Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 101–200 of 1,002
Satoh, T., Sugiura, S., Shin, K., Onuki-Nagasaki, R., Ishida, S., Kikuchi, K., Kakiki, M., & Kanamori, T. (2018) · Lab on a Chip · doi:10.1039/c7lc00952f · Cited by 181
Boyd, N. K., Teng, C., & Frei, C. R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.684515 · Cited by 197
“Developing a repurposed drug, as opposed to a newly discovered compound, has the potential to save more than $1 billion and reduce the time to FDA approval by 50% (Scannell et al., 2012; Beachy et al., 2014).”
BackgroundXu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
“The process of developing novel therapeutics is increasingly slow and costly 1 , with an average of US$2–3 billion spent over the course of 10–15 years to bring a new drug to market 2 .”
Lou, B., & Wu, L. (2021) · MIS Quarterly · doi:10.25300/misq/2021/16565 · Cited by 177
“Accordingly, it is hard to find new drugs, especially those that differ substantially from existing drugs and that provide big improvements (Krieger et al. 2018; Rotman 2019; Scannell et al. 2012).”
Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth
Yadav, V., & Talwar, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.119 · Cited by 172
Kell, D. B., & Goodacre, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.014 · Cited by 169
The Business of Anti-Aging Science
de Magalhães, J. P., Stevens, M., & Thornton, D. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.07.004 · Cited by 165
“In other words, the success rates of clinical trials remain very low [55], and pharmaceutical R&D efficiency has even declined [56], despite what is generally agreed as substantial technological progress in recent decades.”
BackgroundTarín-Pelló, A., Suay-García, B., & Pérez-Gracia, M.-T. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2078308 · Cited by 164
“Currently, commercializing a new molecule costs between 2000 and 3000 million dollars and is a process that lasts between 13 and 15 years [5,94,97].”
BackgroundHigh-throughput organ-on-a-chip systems: Current status and remaining challenges
Probst, C., Schneider, S., & Loskill, P. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.02.004 · Cited by 171
Changing Trends in Computational Drug Repositioning
Yella, J. K., Yaddanapudi, S., Wang, Y., & Jegga, A. G. (2018) · Pharmaceuticals · doi:10.3390/ph11020057 · Cited by 166
“For instance, the total average cost of developing a new drug, as per an estimate, ranges from $2 billion to $3 billion and it takes at least 13–15 years to bring a drug to the market—starting from initial discovery to the approval stage [1].”
BackgroundAdapting Drug Approval Pathways for Bacteriophage-Based Therapeutics
Cooper, C. J., Khan Mirzaei, M., & Nilsson, A. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01209 · Cited by 165
“This lack of interest is not only due to the difficulties in discovering new antibiotic classes but also decreasing financial returns within drug development (Scannell et al., 2012).”
BackgroundInfluentialCross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment
Businaro, L., De Ninno, A., Schiavoni, G., Lucarini, V., Ciasca, G., Gerardino, A., Belardelli, F., Gabriele, L., & Mattei, F. (2013) · Lab Chip · doi:10.1039/c2lc40887b · Cited by 162
Bunker, A., & Róg, T. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.604770 · Cited by 174
“…and Schäfer, 2015; Siuda and Tieleman, 2015; Stepien et al., 2015, 2020; Martinez et al., 2017; Pourmousa and Pastor, 2018; Bengtsen et al., 2020; Schachter et al., 2020); they are tuned via modification of their lipid composition (Augustyn et al., 2019) or alterations to the sequence, thus…”
BackgroundCardiovascular organ-on-a-chip platforms for drug discovery and development
Ribas, J., Sadeghi, H., Manbachi, A., Leijten, J., Brinegar, K., Zhang, Y. S., Ferreira, L., & Khademhosseini, A. (2016) · Applied In Vitro Toxicology · doi:10.1089/aivt.2016.0002 · Cited by 161
“Although most of the scientific and technological fields have seen exponential advances, the past 60 years of drug development has not followed that trend.(29) However, spending continues to increase, with a reported $40 billion expenditure in 2014 in pharmaceutical R&D.”
BackgroundYang, C. G., Zhang, H., Chen, M., Wang, S., Qian, R., Zhang, L., Huang, X., Wang, J., Liu, Z., Qin, W., et al. (2022) · eLife · doi:10.7554/elife.71880 · Cited by 180
“Moreover, it usually takes over 10 years to bring a new drug from bench to bedside, reflecting the complex challenges in this area ( Scannell et al., 2012 ).”
American Trip: Set, Setting, and the Psychedelic Experience in the Twentieth Century
Hartogsohn, I. (2020) · The MIT Press eBooks · doi:10.7551/mitpress/11888.001.0001 · Cited by 183
Network medicine for disease module identification and drug repurposing with the NeDRex platform
Sadegh, S., Skelton, J., Anastasi, E., Bernett, J., Blumenthal, D. B., Galindez, G., Salgado-Albarrán, M., Lazareva, O., Flanagan, K., Cockell, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27138-2 · Cited by 173
“easily accessible manner, and provide walkthroughs of several use cases illustrating the system's flexibility and utility.”
BackgroundUnger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158
The development and use of facial grimace scales for pain measurement in animals
Mogil, J. S., Pang, D., Dutra, G. G. S., & Chambers, C. T. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.07.013 · Cited by 167
Microfluidic Organ/Body-on-a-Chip Devices at the Convergence of Biology and Microengineering
Perestrelo, A. R., Águas, A. C., Rainer, A., & Forte, G. (2015) · Sensors · doi:10.3390/s151229848 · Cited by 165
“, the past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug R&D [199].”
BackgroundInfluentialSrivastava, R. (2021) · ACS Omega · doi:10.1021/acsomega.1c03736 · Cited by 159
Design of efficient computational workflows for in silico drug repurposing
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., Labat, I., & Zhavoronkov, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.019 · Cited by 150
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Shih, H.-P., Zhang, X., & Aronov, A. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.194 · Cited by 160
Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., et al. (2019) · Cancers · doi:10.3390/cancers11091284 · Cited by 146
Is Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All Drugs
Sadri, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01737 · Cited by 162
(2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3743-1 · Cited by 133
Drug screening for human genetic diseases using iPSC models
Elitt, M. S., Barbar, L., & Tesar, P. J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy186 · Cited by 153
Lu, S., Cuzzucoli, F., Jiang, J., Liang, L.-G., Wang, Y., Kong, M., Zhao, X., Cui, W., Li, J., & Wang, S. (2018) · Lab on a Chip · doi:10.1039/c8lc00852c · Cited by 144
AI is a viable alternative to high throughput screening: a 318-target study
Program, T. A. A., Wallach, I., Bernard, D., Nguyen, K. T., Ho, G., Morrison, A., Stecuła, A., Rosnik, A. M., O’Sullivan, A. M., Davtyan, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54655-z · Cited by 149
Transforming nanomedicine manufacturing toward Quality by Design and microfluidics
Colombo, S., Beck‐Broichsitter, M., Boetker, J. P., Malmsten, M., Rantanen, J., & Bohr, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.004 · Cited by 150
Yuan, Q., Gao, J., Wu, D., Zhang, S., Mamitsuka, H., & Zhu, S. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw244 · Cited by 148
“Methods: Approaches based on machine learning for this problem can be divided into two types: feature-based and similarity-based methods.”
MethodEngineering large animal models of human disease
Whitelaw, B., Sheets, T. P., Lillico, S. G., & Telugu, B. P. V. L. (2015) · The Journal of Pathology · doi:10.1002/path.4648 · Cited by 156
“There are many reasons for the high attrition rate during drug discovery [104], with the paucity of reliable animal models being only one.”
BackgroundModgil, S., & Sharma, S. (2016) · Journal of Quality in Maintenance Engineering · doi:10.1108/jqme-10-2015-0048 · Cited by 171
Drug design on quantum computers
(2024) · doi:10.1038/s41567-024-02411-5 · Cited by 132
“Identifying oral drug candidates, the preferred form of drug administration, takes a long time, starting with very weakly binding molecules and taking several years of optimization towards efficacious and safe compounds 1,3,8 .”
Austin, C. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.27 · Cited by 132
Using artificial intelligence methods to speed up drug discovery
Álvarez-Machancoses, Ó., & Fernández‐Martínez, J. L. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1621284 · Cited by 143
“Since most compounds in clinical trials fail due to toxicity or lack of efficacy, the analysis and understanding of mechanisms of action (MoA) of the drugs and the prediction of possible toxicities are two major challenges of drug development [25].”
BackgroundOn the Clinical Pharmacology of Reactive Oxygen Species
Casas, A. I., Nogales, C., Mucke, H. A., Petraina, A., Cuadrado, A., Rojo, A. I., Ghezzi, P., Jaquet, V., Augsburger, F., Dufrasne, F., et al. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019422 · Cited by 140
“Finally, autophagy in response to cellular stress involving ROS leads to programmed cell death (Scherz-Shouval and Elazar, 2011; Sena and Chandel, 2012; Pajares et al., 2017, 2018).”
BackgroundMicroengineered cancer-on-a-chip platforms to study the metastatic microenvironment
Lara, R. P., & Annabi, N. (2016) · Lab on a Chip · doi:10.1039/c6lc00718j · Cited by 138
How AI is being used to accelerate clinical trials
Hutson, M. (2024) · Nature · doi:10.1038/d41586-024-00753-x · Cited by 131
Integrating Human Pluripotent Stem Cells into Drug Development
Engle, S. J., & Puppala, D. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.05.011 · Cited by 137
“Many factors related to efficacy and safety have contributed to this attrition and it seems clear that the drug discovery industry must think differently about how new medicines are developed from the earliest stages of drug discovery in order to maintain a sustainable business model (Sams-Dodd, 2013; Scannell et al.,…”
BackgroundQuality guidelines for oral drug candidates: dose, solubility and lipophilicity
Bayliss, M. K., Butler, J., Feldman, P. L., Green, D. V. S., Leeson, P. D., Palovich, M. R., & Taylor, A. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.007 · Cited by 134
How can attrition rates be reduced in cancer drug discovery?
Moreno, L., & Pearson, A. D. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.768984 · Cited by 127
“Numerous solutions have been proposed to tackle the issue of attrition in anticancer drug development by many authors [5-11], which has even been defined by some as ‘The Valley of Death in anticancer drug development’ [12].”
BackgroundRolinger, L., Rüdt, M., & Hubbuch, J. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02407-z · Cited by 126
“This behavior is termed ’Eroom’s Law’ as it describes the opposite of ’Moore’s Law’ [2].”
Parisi, D., Adasme, M. F., Sveshnikova, A. N., Bolz, S. N., Moreau, Y., & Schroeder, M. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.04.004 · Cited by 135
“Investigating the efficacy of approved or discarded drugs for new indications using an approach called drug repositioning can in fact overcome some of the obstacles in drug discovery, such as the necessity to meet quality standards [6].”
BackgroundPredictive validity in drug discovery: what it is, why it matters and how to improve it
Scannell, J. W., Bosley, J., Hickman, J. A., Dawson, G. R., Truebel, H., Ferreira, G. S., Richards, D. B., & Treherne, J. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00552-x · Cited by 142
Self-citationμOrgano: A Lego®-Like Plug & Play System for Modular Multi-Organ-Chips
Loskill, P., Marcus, S. G., Mathur, A., Reese, W. M., & Healy, K. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139587 · Cited by 125
“Drug research and development is an inefficient, lengthy, and expensive process [1].”
BackgroundIvanenkov, Y. A., Zagribelnyy, B. A., & Aladinskiy, V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00004 · Cited by 132
Engineering inkjet bioprinting processes toward translational therapies
Angelopoulos, I., Allenby, M. C., Lim, M., & Zamorano, M. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27176 · Cited by 130
Yamaguchi, S., Kaneko, M., & Narukawa, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.12980 · Cited by 143
Schwarz, E. M., Hu, Y., Antoshechkin, I. A., Miller, M. M., Sternberg, P. W., & Aroian, R. V. (2015) · Nature Genetics · doi:10.1038/ng.3237 · Cited by 145
Opportunities for Artificial Intelligence in Advancing Precision Medicine
Filipp, F. V. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-00177-4 · Cited by 132
“The pharmaceutical industry rather announced a declining output in terms of the number of new drugs approved despite increasing commercial efforts of drug research and development (2, 3).”
BackgroundHarnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Tundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 125
Parallelization of Molecular Docking: A Review
Dong, D., Xu, Z., Zhong, W., & Peng, S. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180821145215 · Cited by 122
Agoni, C., Olotu, F. A., Ramharack, P., & Soliman, M. E. S. (2020) · Journal of Molecular Modeling · doi:10.1007/s00894-020-04385-6 · Cited by 128
Computational Methodologies in the Exploration of Marine Natural Product Leads
Pereira, F., & Aires‐de‐Sousa, J. (2018) · Marine Drugs · doi:10.3390/md16070236 · Cited by 116
“Although the high-point in the mid to late 1990s appears to be mainly due to regulatory factors [3] (i.”
BackgroundAbductive Reasoning: How Innovators Navigate in the Labyrinth of Complex Product Innovation
Dunne, D. D., & Dougherty, D. J. (2015) · Organization Studies · doi:10.1177/0170840615604501 · Cited by 116
Eastman, A. R. (2016) · Oncotarget · doi:10.18632/oncotarget.12673 · Cited by 129
“There has been much discussion over the past few years about the rate of failure of novel anticancer drugs in clinical trials, and many reasons have been proposed including poor pharmacokinetics and drug bioavailability, unexpected toxicity, lack of efficacy, and regulatory hurdles [2, 3].”
BackgroundRoles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 122
Multinational enterprises and intangible capital
Cadestin, C., Jaax, A., Miroudot, S., & Zürcher, C. (2021) · OECD science, technology and industry policy papers · doi:10.1787/6827b3c9-en · Cited by 113
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“The complexity of these diseases limits the efficacy of commonly used single molecular drug therapeutics, which has led to a critical situation in new drug discovery in recent years [7].”
BackgroundOptimization of Tree Ensembles
Mišić, V. V. (2020) · Operations Research · doi:10.1287/opre.2019.1928 · Cited by 146
Huebsch, N., Charrez, B., Neiman, G., Siemons, B., Boggess, S. C., Wall, S., Charwat, V., Jæger, K. H., Cleres, D., Telle, Å., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00884-4 · Cited by 107
“Briefly, two-step photolithography was used to form a chip composed of: (1) a cell-loading port leading to a cell culture chamber with two large ‘anchoring posts’ and several smaller micro-posts; and (2) a media-loading port leading to media channels running alongside the cell culture chamber.”
MethodIntroducing Therioepistemology: the study of how knowledge is gained from animal research
Garner, J. P., Gaskill, B. N., Weber, E. M., Dallaire, J. A., & Pritchett‐Corning, K. R. (2017) · Lab Animal · doi:10.1038/laban.1224 · Cited by 115
Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry
Tulum, Ö., & Lazonick, W. H. (2018) · International Journal of Political Economy · doi:10.1080/08911916.2018.1549842 · Cited by 127
“…there is convincing evidence that a crisis of productivity afflicts the U.S. pharmaceutical industry (Garnier 2008; Munos 2009; Paul et al. 2010; Pammolli, Magazzini, and Riccaboni 2011; Scannell et al. 2012; Rafols et al. 2014; Gleadle et al. 2014; Kinch 2016; Scannell and Bosley 2016).”
BackgroundPermeability of Epithelial/Endothelial Barriers in Transwells and Microfluidic Bilayer Devices
Frost, T. S., Jiang, L., Lynch, R. M., & Zohar, Y. (2019) · Micromachines · doi:10.3390/mi10080533 · Cited by 119
Mandlik, D. S., & Mandlik, S. K. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1889583 · Cited by 129
Phase 0/microdosing approaches: time for mainstream application in drug development?
Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 119
Yildirim, O., Gottwald, M., Schüler, P., & Michel, M. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00461 · Cited by 117
“The rising cost of drug development (Herper, 2012; Scannell et al., 2012) combining with increasing pressure on drug pricing (Scannell, 2015) challenge current business models of the pharmaceutical industry.”
BackgroundBedload transport: a walk between randomness and determinism. Part 2. Challenges and prospects
Ancey, C. (2020) · Journal of Hydraulic Research · doi:10.1080/00221686.2019.1702595 · Cited by 112
Application of network link prediction in drug discovery
Abbas, K., Abbasi, A., Dong, S., Ling, N., Yu, L., Chen, B., Cai, S., & Hasan, Q. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04082-y · Cited by 122
Aliper, A., Kudrin, R., Polykovskiy, D. A., Kamya, P. R. N., Tutubalina, E. V., Chen, S., Ren, F., & Zhavoronkov, A. A. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3008 · Cited by 122
Financialization and productive models in the pharmaceutical industry
Montalban, M., & Sakinç, M. E. (2013) · Industrial and Corporate Change · doi:10.1093/icc/dtt023 · Cited by 128
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline
Cornet, C., Donato, V. D., & Terriente, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00703 · Cited by 117
Bowen, A., & Casadevall, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504955112 · Cited by 104
“Although such reductionist approaches have facilitated the analysis of enormous candidate drug libraries, there is evidence that techniques used decades ago may have been more effective at identifying clinically relevant molecules (20).”
BackgroundInfluentialWAT-on-a-chip: a physiologically relevant microfluidic system incorporating white adipose tissue
Loskill, P., Thiagarajan, S., Tharp, K. M., Lee-Montiel, F. T., Jeeawoody, S., Reese, W. M., Zushin, P. H., Stahl, A., & Healy, K. E. (2017) · Lab on a Chip · doi:10.1039/c6lc01590e · Cited by 103
Disciplined approach to drug discovery and early development
Plenge, R. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2608 · Cited by 113
The promises of quantitative systems pharmacology modelling for drug development
Knight-Schrijver, V. R., Chelliah, V., Cucurull-Sanchez, L., & Novère, N. G. L. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.002 · Cited by 105
Williamson, A. E., Ylioja, P. M., Robertson, M. N., Antonova‐Koch, Y., Avery, V. M., Baell, J. B., Batchu, H., Batra, S., Burrows, J. N., Bhattacharyya, S. S., et al. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00086 · Cited by 114
LigBuilder V3: A Multi-Target de novo Drug Design Approach
Yuan, Y., Pei, J., & Lai, L. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00142 · Cited by 120
“Although successful drugs have been brought to market with this approach, new drug R&D aiming novel targets was noticeable slowdown and fewer drugs were approved over the last decades (Scannell et al., 2012; Ramsay et al., 2018), which implies the limitation and deficiency of previous single-target drug discovery stra…”
BackgroundBorn, J., Manica, M., Oskooei, A., Cadow, J., Markert, G., & Martínez, M. R. (2021) · iScience · doi:10.1016/j.isci.2021.102269 · Cited by 118
Grafting of 3D Bioprinting to In Vitro Drug Screening: A Review
Nie, J., Gao, Q., Fu, J., & He, Y. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901773 · Cited by 106
Emerging targetome and signalome landscape of gut microbial metabolites
Zheng, X., Cai, X., & Hao, H. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.011 · Cited by 101
Organs-on-a-chip: Current applications and consideration points for in vitro ADME-Tox studies
Ishida, S. (2018) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2018.01.003 · Cited by 106
Analysis of pharma R&D productivity – a new perspective needed
Schuhmacher, A., Hinder, M., Stein, A. V. S. U., Hartl, D., & Gassmann, O. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103726 · Cited by 112
Microfluidic-based vascularized microphysiological systems
Lee, S., Ko, J., Park, D., Lee, B., Chung, M., Lee, Y., & Jeon, N. L. (2018) · Lab on a Chip · doi:10.1039/c8lc00285a · Cited by 99
Deep learning with feature embedding for compound-protein interaction prediction
Wan, F., & Zeng, J. (. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/086033 · Cited by 93
“, single drugs can interact with multiple targets [3], drug developers are seeking to better characterize compound-protein interactions to find new uses of existing drugs (also called drug repositioning or drug repurposing) [3] [4] [5], as it can significantly reduce the time and cost required in drug development [6].”
BackgroundBenchmarking biopharmaceutical process development and manufacturing cost contributions to R&D
Farid, S. S., Baron, M., Stamatis, C., Nie, W., & Coffman, J. (2020) · mAbs · doi:10.1080/19420862.2020.1754999 · Cited by 96
“The pharmaceutical industry has suffered from declining research and development (R&D) productivity and increasing costs over the past few decades.(1,2) The reported capitalized R&D cost to bring a new biopharmaceutical to market has risen from $1.”
BackgroundZhang, P., Wei, Z., Che, C., & Jin, B. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105214 · Cited by 105
Verbist, B. M. P., Klambauer, G., Vervoort, L., Talloen, W., Shkedy, Z., Thas, O., Bender, A., Göhlmann, H. W. H., & Hochreiter, S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.014 · Cited by 108
Pathway-based drug repositioning using causal inference
Li, J., & Lu, Z. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s16-s3 · Cited by 96
“Drug repositioning for poorly treated diseases is a promising strategy in drug discovery today because of the highly unmet need there [5].”
BackgroundAccessing New Chemical Entities through Microfluidic Systems
Rodrigues, T., Schneider, P., & Schneider, G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201400988 · Cited by 101
Nagaraj, A. B., Wang, Q. Q., Joseph, P. L., Zheng, C., Chen, Y., Kovalenko, O., Singh, S., Armstrong, A. J., Resnick, K. E., Zanotti, K. M., et al. (2017) · Oncogene · doi:10.1038/onc.2017.328 · Cited by 94
Wang, Y., Wu, D., Wu, G., Wu, J., Lu, S., Lo, J., He, Y., Zhao, C., Zhao, X., Zhang, H., et al. (2020) · Theranostics · doi:10.7150/thno.38736 · Cited by 93
“On the other hand, animal models for drug testing are labor/time intensive, costly, and most importantly, often yield untranslatable results due to the physiological differences between humans and animal models [11-14].”
BackgroundCecchini, M., Langer, J., & Slawomirski, L. (2015) · Cited by 134
ACID: a free tool for drug repurposing using consensus inverse docking strategy
Wang, F., Wu, F., Li, C., Jia, C., Su, S.-W., Hao, G., & Yang, G. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0394-z · Cited by 95
DeepCPI: A Deep Learning-Based Framework for Large-Scale in Silico Drug Screening
Wan, F., Zhu, Y., Hu, H., Dai, A., Cai, X., Chen, L., Gong, H., Xia, T., Yang, D., Wang, M.-W., et al. (2019) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.04.003 · Cited by 92
“, drug repositioning or drug repurposing) [3,4] to markedly reduce the time and cost required for drug development [5].”
Ellingson, S. R., Smith, J. C., & Baudry, J. Y. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23367 · Cited by 98
Biosimilars: Company Strategies to Capture Value from the Biologics Market
Calo-Fernández, B., & Martinez-Hurtado, J. L. (2012) · Pharmaceuticals · doi:10.3390/ph5121393 · Cited by 92
“There are two main reasons for this deceleration: innovative biotechs had patented and developed products saturating the currently available approved indications, and regulatory agencies require new products to show better efficacy than the existing ones [46–48].”
BackgroundProviding a New Aniline Bioisostere through the Photochemical Production of 1-Aminonorbornanes
Staveness, D., Sodano, T. M., Li, K., Burnham, E. A., Jackson, K. D., & Stephenson, C. R. J. (2018) · Chem · doi:10.1016/j.chempr.2018.10.017 · Cited by 92
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.